These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 35246604

  • 21. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.
    Noack K, Mahendrarajah N, Hennig D, Schmidt L, Grebien F, Hildebrand D, Christmann M, Kaina B, Sellmer A, Mahboobi S, Kubatzky K, Heinzel T, Krämer OH.
    Arch Toxicol; 2017 May; 91(5):2191-2208. PubMed ID: 27807597
    [Abstract] [Full Text] [Related]

  • 22. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
    Jeanteur P.
    Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
    [Abstract] [Full Text] [Related]

  • 23. LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.
    Wang X, Lin Q, Lv F, Liu N, Xu Y, Liu M, Chen Y, Yi Z.
    Leukemia; 2016 Jul; 30(7):1465-74. PubMed ID: 27012866
    [Abstract] [Full Text] [Related]

  • 24. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F, Hasan SK.
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [Abstract] [Full Text] [Related]

  • 25. Activation of G0S2 is coordinated by recruitment of PML/RARα and C/EBPε to its promoter during ATRA-induced APL differentiation.
    Zhang F, Zhu YL, Deng WL, Zhu J, Zhang J.
    J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
    [Abstract] [Full Text] [Related]

  • 26. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
    Orfali N, O'Donovan TR, Cahill MR, Benjamin D, Nanus DM, McKenna SL, Gudas LJ, Mongan NP.
    Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
    [Abstract] [Full Text] [Related]

  • 27. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, Pelicci PG, Müller-Tidow C, Tenen DG, Niederwieser D, Behre G.
    Cancer Res; 2015 Aug 15; 75(16):3411-24. PubMed ID: 26041820
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
    Riccioni R, Saulle E, Militi S, Sposi NM, Gualtiero M, Mauro N, Mancini M, Diverio D, Lo Coco F, Peschle C, Testa U.
    Leukemia; 2003 Jan 15; 17(1):98-113. PubMed ID: 12529666
    [Abstract] [Full Text] [Related]

  • 30. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD.
    Leukemia; 2005 Jul 15; 19(7):1161-8. PubMed ID: 15902297
    [Abstract] [Full Text] [Related]

  • 31. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.
    Esnault C, Rahmé R, Rice KL, Berthier C, Gaillard C, Quentin S, Maubert AL, Kogan S, de Thé H.
    Blood; 2019 Mar 28; 133(13):1495-1506. PubMed ID: 30674471
    [Abstract] [Full Text] [Related]

  • 32. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.
    Jansen JH, Löwenberg B.
    Semin Hematol; 2001 Jan 28; 38(1):37-41. PubMed ID: 11172538
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
    Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R.
    Blood; 1998 Oct 01; 92(7):2244-51. PubMed ID: 9746761
    [Abstract] [Full Text] [Related]

  • 35. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM, He LZ, Warrell RP, Wang ZG, Pandolfi PP.
    Proc Natl Acad Sci U S A; 2000 Aug 29; 97(18):10173-8. PubMed ID: 10954752
    [Abstract] [Full Text] [Related]

  • 36. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17).
    Amin HM, Saeed S, Alkan S.
    Br J Haematol; 2001 Nov 29; 115(2):287-97. PubMed ID: 11703323
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
    Zhou DC, Kim SH, Ding W, Schultz C, Warrell RP, Gallagher RE.
    Blood; 2002 Feb 15; 99(4):1356-63. PubMed ID: 11830487
    [Abstract] [Full Text] [Related]

  • 40. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
    Jing Y, Waxman S.
    Curr Top Microbiol Immunol; 2007 Feb 15; 313():245-69. PubMed ID: 17217047
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.